Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

mthfr support australia pty ltd - alpha lipoic acid,ascorbic acid,ascorbyl palmitate,betacarotene,biotin,calcium citrate tetrahydrate,calcium pantothenate,choline bitartrate,chromium picolinate,colecalciferol,d-alpha-tocopheryl acid succinate,hydroxocobalamin,inositol,levomefolate calcium,magnesium citrate,manganese (ii) glycinate,mecobalamin (co-methylcobalamin),nicotinamide,phytomenadione,potassium iodide,pyridoxal 5-phosphate monohydrate,riboflavin sodium phosphate,selenomethionine,sodium molybdate dihydrate,thiamine -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

mthfr support australia pty ltd - alpha lipoic acid,ascorbic acid,ascorbyl palmitate,betacarotene,biotin,calcium citrate tetrahydrate,calcium pantothenate,choline bitartrate,chromium picolinate,colecalciferol,d-alpha-tocopheryl acid succinate,hydroxocobalamin,inositol,levomefolate calcium,magnesium citrate,manganese (ii) glycinate,mecobalamin (co-methylcobalamin),nicotinamide,phytomenadione,potassium iodide,pyridoxal 5-phosphate monohydrate,riboflavin sodium phosphate,selenomethionine,sodium molybdate dihydrate,thiamine -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.12 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: crospovidone; sodium hydroxide; mannitol; macrogol 6000; hypromellose; sodium starch glycollate; colloidal anhydrous silica; sodium carbonate; calcium stearate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin; purified water; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion:,i) duodenal ulcer ii) gastric ulcer iii) gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis iv) gastrointestinal lesions refractory h2 blockers v) zollinger-ellison syndrome,patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.,3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics:,i) clarithromycin and amoxicillin or ii) clarithromycin and metronidazole or iii) amoxicillin and metronidazole,is recommended in cases

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.56 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; hypromellose; macrogol 6000; sodium carbonate; sodium starch glycollate; colloidal anhydrous silica; sodium hydroxide; calcium stearate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin; purified water; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion:,i) duodenal ulcer ii) gastric ulcer iii) gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis iv) gastrointestinal lesions refractory h2 blockers v) zollinger-ellison syndrome,patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.,3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics:,i) clarithromycin and amoxicillin or ii) clarithromycin and metronidazole or iii) amoxicillin and metronidazole,is recommended in cases

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: lactose monohydrate; magnesium stearate; purified talc; microcrystalline cellulose; triethyl citrate; croscarmellose sodium; colloidal anhydrous silica; purified water; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; quinoline yellow aluminium lake; polyvinyl alcohol; macrogol 3350 - 1. symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastroesophageal reflux disease (gord): - symptomatic gord.the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; gastrointestinal lesions refractory to h2-blockers; zollinger-ellison syndrome; patients whose gastric or duodenal ulceration is not associated with ingestion of nsaids require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; microcrystalline cellulose; magnesium stearate; lactose monohydrate; purified talc; colloidal anhydrous silica; croscarmellose sodium; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - 1. symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastroesophageal reflux disease (gord): - symptomatic gord.the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; gastrointestinal lesions refractory to h2-blockers; zollinger-ellison syndrome; patients whose gastric or duodenal ulceration is not associated with ingestion of nsaids require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; triethyl citrate; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate - 1. symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastroesophageal reflux disease (gord): - symptomatic gord.the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; gastrointestinal lesions refractory to h2-blockers; zollinger-ellison syndrome; patients whose gastric or duodenal ulceration is not associated with ingestion of nsaids require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment.

İsrail - İngilizce - Ministry of Health

gsk consumer healthcare, israel ltd - calcium carbonate; calcium lactate gluconate; colecalciferol - tablets effervescent - calcium lactate gluconate 1358 mg; calcium carbonate 1050 mg; colecalciferol 4 mg - calcium lactate gluconate - calcium lactate gluconate - calcium and vitamin d supplement. calcium helps in the maintenance of bones and teeth. vitamin d helps in the absorption and use of calcium.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.12 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: crospovidone; triethyl citrate; purified water; calcium stearate; carnauba wax; methacrylic acid - ethyl acrylate copolymer (1:1); sodium carbonate; mannitol; povidone; purified talc; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - adults 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ? duodenal ulcer ? gastric ulcer ? gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis ? gastrointestinal lesions refractory to h2 blockers ? zollinger-ellison syndrome patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxicillin or clarithomycin and metronidazole or amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see ?dosage and administration?). 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment. children aged from 5 to 17 years gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis the treatment duration should not exceed 8 weeks.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.56 mg - tablet, enteric coated - excipient ingredients: carnauba wax; triethyl citrate; calcium stearate; mannitol; purified water; sodium carbonate; povidone; macrogol 6000; purified talc; crospovidone; hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - symptomatic relief of heartburn, acid regurgitation and other symptoms associated with gastroesophageal reflux disease (gord).